S Muyldermans
Overview
Explore the profile of S Muyldermans including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
3772
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cawez F, Duray E, Hu Y, Vandenameele J, Romao E, Vincke C, et al.
J Mol Biol
. 2018 Apr;
430(11):1652-1670.
PMID: 29654796
Recent advances in transcriptome sequencing and analysis have revealed the complexity of the human genome. The majority (≈ 98%) of cellular transcripts is not translated into proteins and represents a...
2.
Tillib S, Vyatchanin A, Muyldermans S
Biochemistry (Mosc)
. 2015 Feb;
79(12):1382-90.
PMID: 25716733
In this work, IgG content and structures of antigen-binding domains and hinge regions of different IgG subtypes of Camelus bactrianus were analyzed in detail for the first time. Our data...
3.
Hendrickx M, Zatloukalova M, Hassanzadeh-Ghassabeh G, Muyldermans S, Gils A, Declerck P
J Thromb Haemost
. 2013 Dec;
12(2):229-36.
PMID: 24354544
Background: Down-regulation of fibrinolysis due to cleavage of C-terminal lysine residues from partially degraded fibrin is mainly exerted by the carboxypeptidase activity of activated thrombin-activatable fibrinolysis inhibitor (TAFIa). Recently, some...
4.
Lemaire M, DHuyvetter M, Lahoutte T, Van Valckenborgh E, Menu E, De Bruyne E, et al.
Leukemia
. 2013 Oct;
28(2):444-7.
PMID: 24166214
No abstract available.
5.
Butler J, Wertz N, Sun X, Lunney J, Muyldermans S
Mol Immunol
. 2012 Aug;
53(1-2):140-8.
PMID: 22922509
The immunoglobulin (Ig) genes of many vertebrates have been characterized but IgG subclasses, IgD and IgE proteins are only available for three species in which plasmacytomas occur. This creates a...
6.
Abbady A, Al-Daoude A, Al-Mariri A, Zarkawi M, Muyldermans S
Vet Immunol Immunopathol
. 2012 Apr;
146(3-4):254-63.
PMID: 22472910
The deployment of today's antibodies that are able to distinguish Brucella from the closely similar pathogens, such as Yersinia, is still considered a great challenge since both pathogens share identical...
7.
Caljon G, Caveliers V, Lahoutte T, Stijlemans B, Ghassabeh G, Van Den Abbeele J, et al.
Br J Pharmacol
. 2011 Oct;
165(7):2341-53.
PMID: 22013955
Background And Purpose: Nanobodies are promising antigen-binding moieties for molecular imaging and therapeutic purposes because of their favourable pharmacological and pharmacokinetic properties. However, the capability of monovalent nanobodies to reach...
8.
Hendrickx M, DE Winter A, Buelens K, Compernolle G, Hassanzadeh-Ghassabeh G, Muyldermans S, et al.
J Thromb Haemost
. 2011 Sep;
9(11):2268-77.
PMID: 21883886
Background: Because activated thrombin activatable fibrinolysis inhibitor (TAFIa) has very powerful antifibrinolytic properties, co-administration of t-PA and a TAFIa inhibitor enhances t-PA treatment. Objective: We aimed to generate nanobodies specifically...
9.
Abbady A, Al-Mariri A, Zarkawi M, Al-Assad A, Muyldermans S
Vet Immunol Immunopathol
. 2011 May;
142(1-2):49-56.
PMID: 21592585
Brucella are invasive gram-negative bacteria that multiply and survive within eukaryotic cells causing brucellosis. Syrian (and Middle East) health and economy sectors are still affected by this disease causing a...
10.
Buelens K, Hassanzadeh-Ghassabeh G, Muyldermans S, Gils A, Declerck P
J Thromb Haemost
. 2010 Feb;
8(6):1302-12.
PMID: 20180900
Background And Objective: As activated thrombin-activatable fibrinolysis inhibitor (TAFIa) is a potent antifibrinolytic enzyme, the development of TAFI inhibitors is a new promising approach in the development of profibrinolytic drugs....